Knockout or blockade of Px1 with probenecid in rodents restrains EAE symptoms and results in reduced inflammation and decreased oligodendrocyte damage (Hainz et al., 2017), suggesting that Px1 activity supports damage during MS. This evidence concerns the gene PANX1 and myeloid sarcoma.